Monoclonal antibody TES 23

Drug Profile

Monoclonal antibody TES 23

Alternative Names: Monoclonal antibody TES-23; TES-23

Latest Information Update: 15 Mar 2007

Price : $50

At a glance

  • Originator Chugai Pharmaceutical; Osaka University
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 15 Mar 2007 Discontinued - Preclinical for Solid tumours in Japan (unspecified route)
  • 25 May 1999 Preclinical development for Solid tumours in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top